Skip to content
Information Technology, Medical Health Aged Care

Media Alert: Healthcare Cybersecurity

La Trobe University 2 mins read

A La Trobe academic is available to discuss the growing problem of health data breaches, such as leaking of confidential health information.

The breach of valuable health information in Australia is increasing each year. This rise is attributed to advanced hacking techniques and inadequate cybersecurity practices among health professionals.

Dr Tafheem Wani
Lecturer, Digital Health, at La Trobe’s School of Psychology and Public Health

Dr Wani contributes to research of national importance, such as the development of healthcare cybersecurity frameworks and the enhancement of Victoria's virtual care capabilities.

Contact:
t.wani@latrobe.edu.au or 0451 906 170

Dr Tafheem Wani can discuss the following topics:

  • Healthcare cybersecurity
  • Virtual health, telehealth, and mobile health
  • Organisational challenges in Digital Health Implementations
  • AI in digital health and higher education

The following can be attributed to Dr. Tafheem Wani:

"Healthcare experiences the highest number of data breaches globally and in Australia, over all other industries. With advancements in healthcare technology and digitisation of health services, cybersecurity risks have significantly increased, and can grow even further.

“Hackers are especially interested in health records because they can sell the data for high prices on the black market. They can use the information for medical identity theft, to disrupt health services through non-state actors, and for espionage.

“Healthcare cybersecurity is mostly not given the attention it deserves, and I believe it is about time that all stakeholders – government agencies, healthcare organisations, professionals, and patients alike, recognise and understand their rights and responsibilities in securing health data.

“A significant proportion of data breaches in healthcare are attributed to human or internal errors.* We need a holistic and tailored approach in understanding and developing measures for healthcare cybersecurity. Apart from investments in cybersecurity technology, we also need to invest in initiatives such as developing customised cybersecurity training and awareness programs for healthcare staff, streamlining enforcement of cyber policies and health data privacy regulations, and establishing a proactive cybersecurity culture in healthcare organisations."

*Office of the Australian Information Commissioner (OAIC) for the June December 2023


Contact details:

Elaine Cooney
E.Cooney@latrobe.edu.au
0487 448 734

More from this category

  • Medical Health Aged Care
  • 31/10/2024
  • 17:55
Kyowa Kirin Co., Ltd.

Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company

Masashi Miyamoto to be named Chairman and CEO Abdul Mullick to be named President and COO Changes designed to further deliver on company’s 2030…

  • Contains:
  • Medical Health Aged Care
  • 31/10/2024
  • 12:10
MannKind

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

ICoN-1 study presentation planned November 1 at NTM Symposium AustraliaStudy is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of year DANBURY, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has initiated its first site for its Phase 3 clinical trial evaluating efficacy and safety of Clofazimine Inhalation Suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease. The study,…

  • Business Company News, Medical Health Aged Care
  • 31/10/2024
  • 11:03
Firebrick Pharma

Agreement Signed to Market Nasodine to Healthcare Professionals in Singapore

Firebrick Pharmais pleased to announce that it has executed a Marketing Representation Agreement (the “Agreement”) with Singapore-based, Innorini, trading as Innorini Life Sciences (“Innorini”). The initial term of the Agreement is one year with the option to renew for subsequent one-year terms by mutual agreement. Under the Agreement, Innorini will undertake “Marketing Services” commencing 1 November 2024. The Marketing Services comprise sampling and promotion of Nasodine® Nasal Spray (“Nasodine”) to General Practitioners (“GPs”) and hospital-based doctors and pharmacists (collectively “HCPs”) in Singapore. In addition to building awareness and support of Nasodine by HCPs, Innorini will be expected to sell Nasodine…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.